Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov;134(11):2839-2842.
doi: 10.1038/jid.2014.248. Epub 2014 Jun 16.

DC-HIL+ CD14+ HLA-DR no/low cells are a potential blood marker and therapeutic target for melanoma

Jake Turrentine  1 , Jin-Sung Chung  1 , Kaveh Nezafati  1 , Kyoichi Tamura  1 , Amy Harker-Murray  2 , James Huth  2 , Rohit R Sharma  2 , David B Harker  3 , Kiyoshi Ariizumi  4 , Ponciano D Cruz Jr  1
Affiliations

DC-HIL+ CD14+ HLA-DR no/low cells are a potential blood marker and therapeutic target for melanoma

Jake Turrentine et al. J Invest Dermatol. 2014 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors state no conflict of interest.

Figures

Figure 1
Figure 1. Positive correlation between DC-HIL+CD14+HLA-DRno/low cells and melanoma stage
PBMCs from melanoma patients (stages 0-IV) or dysplastic nevus (DN), and from healthy donors (HD) were analyzed for CD14 vs. HLA-DR expression, in which CD14+HLA-DRno/low cells are indicated (%). These cells were FACS-gated and examined for expression of DC-HIL vs. CD14. Data shown are representative of each group (a). % CD14+HLA-DRno/low (b) or % DC-HIL+CD14+HLA-DRno/low cells/PBMC (c) in each cohort is summarized (mean % ± sd). Statistical significance for each stage was calculated by comparison with HD. (d) % blood DC-HIL+CD14+HLA-DRno/low cells/PBMCs was assayed at indicated times post-resection in 9 patients with stage 0 melanoma (data for patient M71 are in red), *p<0.001 and **p<0.01.
Figure 2
Figure 2. Anti-DC-HIL mAb treatment restored IFN-γ response in melanoma patients
(a) CD14+HLA-DRno/low cells from stage III patient or healthy donor cocultured with T-cells/HLA-DR+ cells (varying ratios) with anti-CD2/CD3/CD28 Ab. (b) Effect of anti-DC-HIL or control IgG on IFN-γ secretion by the coculture (1:1 cell ratio) is expressed as IFN-γ amount (%) relative to T-cell culture: 50 and 53 ng/ml for HD and melanoma, respectively (a); and 24 ng/ml for (b). Representative data of 3 different patients. (c) PBMCs from same patients with stages III/IV were cultured with Ab; fold increase in IFN-γ amounts (mAb vs. IgG) is shown with Pearson’s correlation coefficient r. (d) Same experiments were performed with all samples, and values of fold increase in IFN-γ production plotted to cancer stage. *p<0.001.
See this image and copyright information in PMC

References

    1. Chung JS, Dougherty I, Cruz PD, Jr, et al. Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation. J Immunol. 2007a;179:5778–84. - PubMed
    1. Chung JS, Sato K, Dougherty, et al. DC-HIL is a negative regulator of T lymphocyte activation. Blood. 2007b;109:4320–7. - PMC - PubMed
    1. Chung JS, Tomihari M, Tamura K, et al. The DC-HIL ligand syndecan-4 is a negative regulator of T-cell allo-reactivity responsible for graft-versus-host disease. Immunology. 2013;138:173–82. - PMC - PubMed
    1. Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58:49–59. - PMC - PubMed
    1. Filipazzi P, Valenti R, Huber V, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25:2546–53. - PubMed

Publication types

MeSH terms